Rhythm Pharmaceuticals (RYTM) Current Assets (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Current Assets of $430.1 million for Q1 2026, up 16.46% year-over-year from $369.3 million in Q1 2025, and down 7.89% quarter-over-quarter from $466.9 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Current Assets (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Current Assets for 11 consecutive years, with $430.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 16.46% year-over-year to $430.1 million; the TTM figure through Mar 2026 stood at $430.1 million (up 16.46% YoY), while the FY2025 annual figure was $466.9 million, up 24.78% from the prior year.
- Current Assets retreated to $430.1 million in Q1 2026 per RYTM's latest filing, from $466.9 million in the prior quarter.
- Across five years, Current Assets topped out at $494.8 million in Q3 2025 and bottomed at $235.8 million in Q1 2024.
- Historically, Current Assets has averaged $346.3 million across 5 years, with a median of $354.2 million in 2022.
- Annual changes were most pronounced in 2022 — Current Assets tumbled 38.5% — and 2025, when it soared 56.64%.
- Rhythm Pharmaceuticals' Current Assets stood at $354.2 million in 2022, then fell by 12.98% to $308.3 million in 2023, then advanced by 21.39% to $374.2 million in 2024, then climbed by 24.78% to $466.9 million in 2025, then retreated by 7.89% to $430.1 million in 2026.
- Business Quant data shows RYTM's Current Assets at $430.1 million in Q1 2026, $466.9 million in Q4 2025, and $494.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 426.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 426.56 Mn |
| Mar 31, 2026 | 430.09 Mn |
| Dec 31, 2025 | 466.92 Mn |
| Sep 30, 2025 | 494.80 Mn |
| Jun 30, 2025 | 360.68 Mn |
| Mar 31, 2025 | 369.29 Mn |
| Dec 31, 2024 | 374.20 Mn |
| Sep 30, 2024 | 340.34 Mn |
| Jun 30, 2024 | 357.37 Mn |
| Mar 31, 2024 | 235.75 Mn |
| Dec 31, 2023 | 308.27 Mn |
| Sep 30, 2023 | 329.20 Mn |
| Jun 30, 2023 | 283.88 Mn |
| Mar 31, 2023 | 317.84 Mn |
| Dec 31, 2022 | 354.24 Mn |
| Sep 30, 2022 | 361.87 Mn |
| Jun 30, 2022 | 249.33 Mn |
| Mar 31, 2022 | 253.45 Mn |
| Dec 31, 2021 | 308.39 Mn |
| Sep 30, 2021 | 335.64 Mn |